# BioMarkerX — Comprehensive Forensic Novelty Audit Report

## Executive Summary & Scientific Verdict
This report provides an exhaustive, un-biased forensic audit of all proposed novelties in the BioMarkerX project.

### **Key Audit Takeaways**
1. **Cohort Lineage Correction**: The reported 5,999-patient cohort is **NOT independent external validation**. It overlaps 3,362 validation patients and 2,638 locked-test patients from PhysioNet Set A. It must be described as a *Reserved Same-Source Holdout*.
2. **99.63% Sensitivity Reconciliation**: The 99.63% figure is an un-constrained post-hoc screening coverage metric with an 82% patient false-positive rate. It does NOT replace the canonical lead-time-constrained **84.95% sensitivity** (237/279).
3. **Temperature Scaling AUROC Proof**: Temperature scaling ($T=1.12$) is a strictly monotonic transformation. Mathematical proof confirms **AUROC difference = $0.000000$**. AUROC changes were driven by dataset slicing, NOT temperature scaling.
4. **Vasopressor Proxy Deconstruction**: `VasopressorProxy` is a synthetic proxy derived from Shock Index (`HR/SBP > 0.9`) with a manual coefficient of 5.0. It is a heuristic filter, NOT a drug-dose validated formula.
5. **Verified Core Novelty**: The **Dual-Tier Asymmetric Architecture** (silent screening + high-precision confirmation PPV) is **SCIENTIFICALLY SUPPORTED AND DEFENSIBLE**.

## Master Verdict Summary
- **PROVEN**: Dual-Tier Decoupling, Causal Expanding Baseline Normalization, 84.95% Locked Sensitivity, 36h Median Lead Time.
- **PROMISING**: Second-Order Acceleration ($\Delta^2\text{MAP}$), LOS-Adaptive Persistence.
- **WRONG / RE-LABELED**: Calling PhysioNet Set A slice 'External Validation', attributing AUROC gain to Temperature Scaling, describing Shock Index proxy as 'Vasopressor Dose'.
